REPORT DOCUMENTATION PAGE

Form Approved OMB No. 0704-0188

The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Service Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.

person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ORGANIZATION.						
1. REPORT DATE (DD-MM-YYYY) 2. REPORT TYPE Poster						3. DATES COVERED (From - To) 08/20-23/2018
4. TITLE AND SUBTITLE					5a. CONTRACT NUMBER	
Effects of Temperature Correction on Key Arterial Blood Gas						
Measures in a Combat Relevant Trauma Model Treated with					5b. GRANT NUMBER	
Therapeutic Hypothermia: Implications for Prolonged Field						
Care					5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S)					5d. PROJECT NUMBER	
Lt Col Sams, Valerie G						
					5e. TASK NUMBER	
					5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)					l	8. PERFORMING ORGANIZATION
59th Clinical Investigations and Research Support						REPORT NUMBER
1100 Wilford Hall Loop, Bldg 4430 JBSA – Lackland, TX 78236-9908						18008
210-292-7141						
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)						10. SPONSOR/MONITOR'S ACRONYM(S)
59th Clinical Investigations and Research Support						
1100 Wilford Hall Loop, Bldg 4430 JBSA – Lackland, TX 78236-9908						11. SPONSOR/MONITOR'S REPORT
210-292-7141						NUMBER(S)
12. DISTRIBUTION/AVAILABILITY STATEMENT						
Approved for public release. Distribution is unlimited.						
13. SUPPLEMENTARY NOTES						
MHSRS 2018, Kissimmee, FL 20-23 Aug 2018						
14. ABSTRACT						
15. SUBJECT TERMS						
16. SECURITY (CLASSIFICATIO	N OF:	17. LIMITATION OF	18. NUMBER	19a. NAN	/IE OF RESPONSIBLE PERSON
	b. ABSTRACT	c. THIS PAGE	ABSTRACT	OF PAGES		Erin Toth
			I AGES	19b. TEL	EPHONE NUMBER (Include area code)	

INSTRUCTIONS FOR COMPLETING SF 298

- **1. REPORT DATE.** Full publication date, including day, month, if available. Must cite at least the year and be Year 2000 compliant, e.g. 30-06-1998; xx-06-1998; xx-xx-1998.
- **2. REPORT TYPE.** State the type of report, such as final, technical, interim, memorandum, master's thesis, progress, quarterly, research, special, group study, etc.
- **3. DATES COVERED.** Indicate the time during which the work was performed and the report was written, e.g., Jun 1997 Jun 1998; 1-10 Jun 1996; May Nov 1998; Nov 1998.
- **4. TITLE.** Enter title and subtitle with volume number and part number, if applicable. On classified documents, enter the title classification in parentheses.
- **5a. CONTRACT NUMBER.** Enter all contract numbers as they appear in the report, e.g. F33615-86-C-5169.
- **5b. GRANT NUMBER.** Enter all grant numbers as they appear in the report, e.g. AFOSR-82-1234.
- **5c. PROGRAM ELEMENT NUMBER.** Enter all program element numbers as they appear in the report, e.g. 61101A.
- **5d. PROJECT NUMBER.** Enter all project numbers as they appear in the report, e.g. 1F665702D1257; ILIR.
- **5e. TASK NUMBER.** Enter all task numbers as they appear in the report, e.g. 05; RF0330201; T4112.
- **5f. WORK UNIT NUMBER.** Enter all work unit numbers as they appear in the report, e.g. 001; AFAPL30480105.
- **6. AUTHOR(S).** Enter name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. The form of entry is the last name, first name, middle initial, and additional qualifiers separated by commas, e.g. Smith, Richard, J, Jr.
- 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES). Self-explanatory.

- **8. PERFORMING ORGANIZATION REPORT NUMBER.** Enter all unique alphanumeric report numbers assigned by the performing organization, e.g. BRL-1234; AFWL-TR-85-4017-Vol-21-PT-2.
- **9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES).** Enter the name and address of the organization(s) financially responsible for and monitoring the work.
- **10. SPONSOR/MONITOR'S ACRONYM(S).** Enter, if available, e.g. BRL, ARDEC, NADC.
- **11. SPONSOR/MONITOR'S REPORT NUMBER(S).** Enter report number as assigned by the sponsoring/monitoring agency, if available, e.g. BRL-TR-829; -215.
- **12. DISTRIBUTION/AVAILABILITY STATEMENT.** Use agency-mandated availability statements to indicate the public availability or distribution limitations of the report. If additional limitations/ restrictions or special markings are indicated, follow agency authorization procedures, e.g. RD/FRD, PROPIN, ITAR, etc. Include copyright information.
- **13. SUPPLEMENTARY NOTES.** Enter information not included elsewhere such as: prepared in cooperation with; translation of; report supersedes; old edition number, etc.
- **14. ABSTRACT.** A brief (approximately 200 words) factual summary of the most significant information.
- **15. SUBJECT TERMS.** Key words or phrases identifying major concepts in the report.
- **16. SECURITY CLASSIFICATION.** Enter security classification in accordance with security classification regulations, e.g. U, C, S, etc. If this form contains classified information, stamp classification level on the top and bottom of this page.
- **17. LIMITATION OF ABSTRACT.** This block must be completed to assign a distribution limitation to the abstract. Enter UU (Unclassified Unlimited) or SAR (Same as Report). An entry in this block is necessary if the abstract is to be limited.





Effects of Temperature Correction on Arterial Blood Gas Values in a Combat Relevant Model of Lung Injury Treated with Therapeutic Hypothermia: Implications for Prolonged Field Care

Kyle Sieck, BS¹, Daniel Wendorff, BS¹, Brendan Beely, RRT¹, George Harea, BS¹, Jae Hyek Choi, PhD, DVSc¹, Alexander Dixon, BS¹, Teryn

Antonio, San Antonio, TX

Roberts, MS^{1,2}, Vitali Karaliou, MD¹, Leopoldo Cancio, MD³, Valerie Sams, MD⁴, Andriy Batchinsky, MD^{1,2}

¹ The Geneva Foundation, Tacoma WA, ²Morsani College of Medicine, University of South Florida, Tampa, FL ³United States Army Institute of Surgical Research, JBSA-Ft. Sam Houston, TX, ⁴59th Medical Wing, Joint Base San



The opinions or assertions contained herein are the private views of the author and are not to be construed as official or as reflecting the views of the Department of the Air Force, the Department of Defense, or The Geneva Foundation.

Introduction

Therapeutic hypothermia may be beneficial in preventing reperfusion related damage after trauma

Blood gas analysis is crucial for the monitoring of patients after lung injury

Standard arterial blood gas analysis involves heating of arterial blood to a reference physiological temperature of 37°C


Algorithms blood can mathematically calculate the patient's blood gas at actual body temperature from the standard 37°C temperature blood gas value

Objective

We hypothesized that point-of-care blood gas analysis of hypothermic patients provides a systematic under estimation of values for pO2 and pCO₂ compared to reference temperature

Methods

The temperature corrected and the 37°C arterial blood gases were recorded at Baseline, post-Shock, post-Pneumonectomy, post-Transfusion, and every 6 hours after transfusion using i-STAT point of care blood gas analyzers (Abbott, Abbott



Hilum clamp

up to 24 hrs after injury


Clamped right lung hilum

Fluid resuscitation **Blood transfusion** Cooled to 32°C with ICU care and observation

ml/kg, 30 min after completion of hemorrhage, followed by transfusion of all shed blood.

Ringer's lactate ~36

Statistical analysis by SAS, 9.4, Cary, NC. (p<0.5), data presented as means±SEM, statistics by Kruskal-Wallis test with a Dunnett adjustment




Site of impact

Chest Tube


pShock






Mobilization of the Right Lung Bleeding from Femoral Artery


Results pTrans pPneumo 37.2±0.35 | 32.0±0.03 | 31.9±0.09 | 31.7±0.22 | 32.1±0.11



*Significant difference (p<0.5) between 37°C and patient-temperature corrected values, data presented as means±SEM, statistics by Kruskal-Wallis test with a Dunnett adjustment



*Significant difference (p<0.5) between 37°C and patient-temperature corrected values, data presented as means±SEM, statistics by Kruskal-Wallis test with a Dunnett adjustment



*Significant difference (p<0.5) between 37°C and patienttemperature corrected pH values, data presented as means±SEM, statistics by Kruskal-Wallis test with a Dunnett adjustment

Conclusion

Blood gas analysis during Therapeutic Hypothermia at 32°C showed a systematic underestimation of pO2 values by about 22-26 mm Hg

The effects on pH and pCO2 were although significant statistically but clinically of less potential impact

The patient-temperature corrected blood gas values are crucial for monitoring patients treated with TH suggesting that new nomograms for temperature correction should be developed to include commonly used therapeutic targets recommended for specific Therapeutic Hypothermia protocols

Acknowledgements

This study was funded by the United States Air Force, and administered through the 59th MDW via The Geneva Foundation under Contract #FA8650-15-C-6692, PI: Dr. Andriy Batchinsky, MD. The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended.